Drugs / LAE005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05390710 | Jun 2021 → Dec 2023 | triple-negative breast carcinoma | Laekna Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-04-09 | Laekna Limited | Results AACR 2024 Presentation of Laekna | Afuresertib Demonstrated Promising Treatment Benefit in Combination Therapy for Drug-resistant TNBC Patients
AACR 2024 Presentation of Laekna | Afuresertib Demonstrated Promising Treatment Benefit in Combination Therapy for Drug-resistant TNBC Patients laekna.com ↗
The combination therapy of afuresertib plus LAE005 and nab-paclitaxel is well tolerated and has demonstrated preliminary anti-tumor efficacy in locally advanced/metastatic TNBC who were resistant to prior chemotherapy, immune checkpoint inhibitor therapy, or PARP inhibitor therapy. |
All press releases naming this drug 1 release
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAE005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05390710 ↗ |
| Route | Intravenous | “LAE005: 1200 mg IV Q3W” NCT05390710 ↗ |